All In Biotech

Drug Trial Radar · NCT07459504

SMART Diets for MASLD

A Sequential Multiple Assignment Randomized Trial of Diet Treatments for Hepatic Steatosis and Cardiometabolic Risk in Youth

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 102 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

102

Planned (sponsor's estimate)

Start

Nov 5, 2026

Primary completion

Dec 26, 2029

Study completion Dec 26, 2030

Sponsor

Lead sponsor
Michigan State UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Emory University; Corewell Health West; National Heart, Lung, and Blood Institute (NHLBI)
First posted
Mar 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 11 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase 2 trial is a single-site sequential, multiple assignment, randomized trial (SMART) to test and construct a high-quality adaptive intervention of essential amino acids (EAA) and/or Low Sugar Diet for children with metabolic dysfunction associated steatotic liver disease (MASLD) and increased cardiometabolic risk. The basis for the trial includes high-quality pilot data in both EAA for hepatic steatosis and a low sugar diet for hepatic steatosis. In the trial, children aged 11-17 years old will be eligible to participate if their BMI is greater than or equal to 95th% at baseline and hepatic steatosis is greater than or equal to 8% at baseline by Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) because this is the most common age group diagnosed with metabolic-dysfunction associated steatotic liver disease.

Conditions

  • Metabolic-dysfunction Associated Steatotic Liver Disease

Interventions

  • Essential Amino Acids Supplementation interventionDrug

    EAA supplement contains the following formulation: histidine, isoleucine, leucine, lysine, phenylalanine, threonine, and valine

  • Low sugar dietOther

    The Low Sugar Diet uses the adapted and extended Social Cognitive Theory (SCT) guided low sugar intervention. The registered dietitian nutritionist (RDN) helps families to identify foods high in sugar and to identify acceptable replacements in order to remove foods and drinks high in free sugar from the home and replacement with low or no free sugar containing similar foods.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in hepatic steatosisTime frame: Baseline to 24 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Corewell Health West

    Grand Rapids, Michigan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.